SB269652
Dopamine receptor modulator
From Wikipedia, the free encyclopedia
SB269652 is an experimental dopamine D2 and D3 receptor negative allosteric modulator.[1][2] It is of interest in the potential development of novel antipsychotics for treatment of schizophrenia with reduced side effects, such as extrapyramidal symptoms.[1][2] The drug is described as a dual orthosteric and allosteric (i.e., bitopic) modulator of the dopamine D2 and D3 receptors, as an atypical allosteric modulator of these receptors, and as specifically targeting D2–D3 receptor dimers.[1][2] SB269652 was first described in the scientific literature by 1999.[3][4] It was originally thought to act purely as an antagonist of the dopamine D2 and D3 receptors, but was serendipitously found to be a negative allosteric modulator of these receptors in 2010.[1][2] It was the first dopamine D2 and D3 receptor negative allosteric modulator to be discovered.[1] More potent analogues of SB269652 have been developed.[2][5]
| |
| Clinical data | |
|---|---|
| Other names | SB-269652; SB-269,652 |
| Drug class | Dopamine D2 and D3 receptor negative allosteric modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H30N4O |
| Molar mass | 426.564 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
